Advertisements

Ephedrin Biotika

Quick links to important sections

Ephedrin Biotika

Advertisements
Advertisements

Treatment option: Asthma, Bronchospasm

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ephedrin Biotika

Ephedrin Biotika is a medicinal preparation defined by its active ingredient, Ephedrine hydrochloride, and its established role as a powerful systemic stimulant. It is clinically recognized for its use in supporting the circulatory and respiratory systems, particularly when rapid intervention is required.


Quick Facts

Property Description
Active ingredient Ephedrine hydrochloride
Form Sterile solution for injection (ampoules)
Pharmacological class Adrenergic agonist, Sympathomimetic amine
General purpose Systemic support for circulation and respiration
Origin Synthetic compound

Classification and Active Substance

Ephedrin Biotika is classified as a sympathomimetic amine and an adrenergic agonist, designed to act systemically throughout the body. The active core of this medicine is Ephedrine hydrochloride, which is a synthetic compound structurally related to naturally occurring plant alkaloids. The compound is chemically defined as alpha-[1-(methylamino)ethyl]benzyl alcohol hydrochloride. The Ephedrin Biotika brand is typically a prescription-only medicine (Rx) and is manufactured as an immediate-acting formulation.

The primary mechanism of Ephedrine involves both the direct stimulation of receptors and the indirect release of endogenous norepinephrine. This means the drug works by both mimicking and amplifying the body's natural stress responses.


Dual Action and Pharmaceutical Form

The general therapeutic purpose of Ephedrin Biotika is to simultaneously affect the circulatory and respiratory systems by providing rapid, systemic support. Ephedrine achieves this by inducing vasoconstriction (the narrowing of blood vessels) and bronchodilation (the widening of airways).

Ephedrine acts as a non-selective sympathomimetic, characterized by its role in causing both vasoconstrictive and bronchodilatory effects. The final preparation is a sterile solution for injection, supplied in sealed ampoules, a format necessary for delivering its effects without delay. This parenteral administration route is a differentiating factor, as it prioritizes rapid absorption over the sustained release of oral formulations.

Regulatory References

  1. Therapeutic Goods Administration (TGA) Product Information for Ephedrine
Advertisements

What side effects are possible with Ephedrin Biotika?

Possible Side Effects and Safety Information

The safety profile of Ephedrine hydrochloride is largely defined by its potent action as a sympathomimetic amine, resulting in documented adverse reactions that primarily affect the cardiovascular and central nervous systems. Regulatory documents classify these effects by frequency and System-Organ Class (SOC).

Frequency-Classified and Systemic Reactions

Adverse reactions listed as Common in official labeling include anxiety, restlessness, insomnia, tremor, headache, nausea, vomiting, palpitations, and hypertension. Effects are grouped by the systems involved, such as Cardiac disorders (e.g., tachycardia, palpitations) and Nervous system disorders (e.g., tremor, headache).

Reactions classified as Rare or where the Frequency is Not Known include more severe events like certain cardiac arrhythmias, acute pulmonary edema, and myocardial infarction.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions explicitly highlighted in official prescribing information include Severe Hypertension (hypertensive crisis) and significant Cardiac Arrhythmias. Safety documentation notes a high-level constraint regarding the risk of a hypertensive crisis when Ephedrine is used concomitantly with Monoamine Oxidase Inhibitors (MAOIs).

Specific safety considerations are documented for certain populations. Older adults may have increased sensitivity to the cardiovascular and central nervous system effects, and have an increased risk of developing urinary retention. Furthermore, official labeling advises against use during breast-feeding due to the drug being excreted in milk, with documented effects in infants.

Regarding exposure, regulatory data indicates that Tachyphylaxis (rapidly decreasing response) and Tolerance may be observed following repeated or prolonged administration.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Ephedrine hydrochloride documents the potential for severe and life-threatening events primarily involving the central nervous and cardiovascular systems. Symptoms observed following overdosage include hypertension, tachycardia, palpitations, and the occurrence of ventricular and supraventricular arrhythmias.

CNS toxicity is a key manifestation, with documented signs such as convulsions, coma, paranoid psychosis, hallucinations, and restlessness. Other systemic presentations include fever, nausea, vomiting, and respiratory depression.

Classification Official Regulatory Statement
Severity Classification Potential for Severe and Life-Threatening events.
Toxicity Data Estimated lethal dose in humans is approximately 2 g.
Population Notes The elderly are more sensitive to the cardiovascular effects.

Urgent medical attention is strictly required for any suspected overdose due to the potential for these life-threatening events. Regulatory guidance states that the management of severe overdosage may necessitate intensive supportive treatment in a monitored setting. Procedural instructions include the possibility of emptying the stomach by emesis and lavage, and specific medical interventions are documented, such as the use of labetalol for certain supraventricular arrhythmias, which necessitates electrocardiograph monitoring.

Advertisements

Therapeutic Uses of Ephedrin Biotika

Quick Facts: Uses of Ephedrin Biotika

  • Supports the management of low blood pressure (hypotension).
  • Utilized for low blood pressure occurring in the context of anesthesia.
  • Employed to assist in addressing certain allergic conditions, such as bronchial asthma.

Ephedrin Biotika is a medication primarily indicated for the treatment of clinically significant low blood pressure (hypotension) that may arise during anesthesia. This use assists in maintaining appropriate blood pressure levels during a surgical procedure or immediately following it.

The therapeutic domain of this product also encompasses its application for addressing certain conditions like bronchial asthma. In this context, it may support temporary relief of associated symptoms such as shortness of breath, chest tightness, and wheezing. Furthermore, ephedrine may be used to manage symptoms of allergic disorders and nasal congestion.

Patients should consult a healthcare professional to determine if this medication is appropriate for their specific condition. The full range of approved uses is detailed in official regulatory documents and the product information provided by the manufacturer.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Ephedrin Biotika

The eligibility profile for Ephedrin Biotika (Ephedrine hydrochloride) is defined by strict regulatory categories, clarifying who is permitted, restricted, or prohibited from using the medicine. Use is primarily established for adults requiring the treatment of hypotension during anesthesia.

Classification Population or Condition
Contraindicated Patients with hypersensitivity, phaeochromocytoma, asymmetric septal hypertrophy, closed-angle glaucoma, or those receiving Monoamine Oxidase Inhibitors (MAOIs) [Source 1.4].
Conditional Use Patients with impaired renal function, hypertension, diabetes mellitus, or hyperthyroidism [Source 1.4].
Not Established Pediatric population (children and adolescents); safety and effectiveness have not been established by regulatory authorities [Source 1.6].
Not Recommended Breastfeeding women [Source 1.6].

Age-Related Eligibility: While established in adults, use in the pediatric population is generally not recommended due to insufficient data. Older adults require caution, with dosage consideration given to the higher frequency of decreased organ function [Source 1.6].

Pregnancy Status: Available data have not identified a drug-associated risk of birth defects, but specific clinical caution is advised regarding neonatal metabolic acidosis and fetal heart rate when used near delivery [Source 1.1].

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Restrictions

The official interaction profile for Ephedrin Biotika is defined by its sympathomimetic action, resulting in several mandatory restrictions. Co-administration with Non-selective Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the risk of severe hypertensive crisis and hyperthermia; this prohibition requires a 14-day mandatory separation period after stopping the MAOI drug. Concomitant use with Oxytocic Drugs (such as Oxytocin) is also officially contraindicated due to the documented risk of serious postpartum hypertension, which has been associated with stroke. Other Indirect Sympathomimetic Agents and Ergot Alkaloids are likewise restricted combinations.

Clinically Significant Interactions and Exposure Alterations

Interactions that augment the pressor effect of Ephedrine include Clonidine, Propofol, and Atropine. Conversely, drugs that antagonize the pressor effect include Alpha- or Beta-adrenergic Antagonists and Guanethidine, where co-administration may lead to a loss of antihypertensive effectiveness. Volatile Liquid Anesthetics and Cardiac Glycosides are associated with an increased possibility of arrhythmias. A documented pharmacokinetic interaction shows Ephedrine increases the clearance of Dexamethasone, and it may increase the plasma concentration of certain Antiepileptics, such as Phenytoin and Primidone. Official labeling also recommends avoidance of caffeine and dietary supplements with stimulant effects.

Advertisements

Mechanism of Action

The final text describes the molecular interaction and resulting system-level physiological changes.

Ephedrine is a sympathomimetic amine that primarily acts by modulating the release of norepinephrine (NE) from presynaptic neuronal terminals. Ephedrine enters the neuron via the Norepinephrine Transporter (NET), where it then interacts with the Vesicle Monoamine Transporter 2 (VMAT2). This interaction promotes the displacement of stored NE from its vesicular reserves into the neuronal cytoplasm.

The resulting elevated concentration of free NE within the cytoplasm facilitates the reversal of the NET, causing a rapid efflux of NE into the synaptic cleft. This increased synaptic NE concentration leads to heightened stimulation of postsynaptic alpha- and beta-adrenergic receptors.

Activation of alpha1-adrenergic receptors in peripheral vascular smooth muscle induces vasoconstriction, while stimulation of cardiac beta1-adrenergic receptors results in both positive chronotropy (increased heart rate) and positive inotropy (increased contractility). Activation of beta2-adrenergic receptors on bronchial smooth muscle promotes bronchodilation. These effects collectively modulate systemic vascular resistance and cardiac output.

Advertisements

Dosage and Administration Information

Official Administration Instructions (Intravenous Use)

Ephedrin Biotika solution for injection is strictly administered via the intravenous (IV) route and is intended for use in a controlled clinical environment, primarily for the treatment of hypotension occurring during anesthesia. Administration must be performed solely by or under the supervision of the anesthetist.

Dosing and Frequency

For adults, including the elderly, the official initial dose is typically 3 to 6 mg (with a maximum of 9 mg) administered as a slow intravenous injection (bolus). This dose is administered on an as-needed basis and may be repeated every 3 to 4 minutes until the desired blood pressure is achieved. The total dose administered within a single procedure should not exceed 30 mg, and the maximum total dosage over a 24-hour period should not exceed 150 mg.

Preparation and Procedural Steps

Before administration, the medicinal product must be visually inspected. The solution should be clear and colorless and must not contain any visible particles; if discoloration or particles are present, the product should not be used. Depending on the product concentration available, the solution may need to be diluted to a final concentration (e.g., 3 mg/mL or 5 mg/mL) using suitable intravenous fluids such as 0.9% Sodium Chloride Injection or 5% Glucose/Dextrose Injection. Dosing must always be carefully titrated to effect to meet the individual patient's blood pressure goal. The use in children under 12 years is generally not recommended due to insufficient data.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ephedrin Biotika

Ephedrin Biotika (Ephedrine hydrochloride) was studied for its role in acute situations. Research focused on how it was associated with changes in vital systemic function. The evidence base is concentrated in two major areas: its use to manage blood pressure in surgical settings, and historical studies related to respiratory conditions. The overall evidence quality varies across studies depending on the specific application being evaluated in.


Evidence for Use in Managing Hypotension during Anesthesia

The research base for managing low blood pressure that was observed in patients during surgical procedures and anesthesia primarily includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These study designs were used in research exploring how frequently studies examined the medication's association with blood pressure changes.

The outcomes research examined primarily focused on short-term physiological imbalance, such as changes in Systolic and Mean Arterial Pressure and heart rate measured in the minutes following administration. Findings indicate that studies described patterns in blood pressure measurements in the observed populations.

Follow-up durations were limited in this research domain, as the studies are focused on the immediate period surrounding the operation. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding patients who received the injection during surgery.


Historical Research for Bronchial Asthma

The body of evidence related to ephedrine's use in conditions associated with acute or disruptive episodes like bronchial asthma is considered largely historical. Studies explored this application using older clinical trial designs and observational settings applied in research contexts involving fluctuating or unstable symptoms of the respiratory system.

Evidence is limited for this indication in the context of modern treatment. The existing research contributes to the broader evidence landscape but often compared ephedrine to therapies used in the past, meaning evidence is limited against more recently developed, selective agents. This means that the certainty remains low regarding its present-day role for this type of condition.


Evidence in Special Patient Populations

Specific studies were evaluated in certain groups, such as pregnant patients and older adults. For instance, the use of ephedrine was studied for managing low blood pressure in pregnant patients undergoing Cesarean delivery. Subgroup findings are uncertain in some of these highly specific trials when comparing ephedrine to other pressor agents used in this setting.

For older adults and pediatric subgroups, data for certain groups remain insufficient. While research was associated with general findings, results apply only to the populations studied, and there are limited data to provide comprehensive insight into its patterns of action in all age groups or those with complex existing health issues.

Key Studies & References

  1. Ephedrine - StatPearls - NCBI Bookshelf (General Review and Indications)
  2. Attachment: Extract from Clinical Evaluation Report Ephedrine hydrochloride - Therapeutic Goods Administration (TGA)
  3. Summary of Product Characteristics (SmPC) - Ephedrine Hydrochloride Solution for Injection (HPRA)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ephedrin Biotika (FAQ)


Q: How quickly should I expect Ephedrin Biotika to start working?

A: Official information confirms that Ephedrin Biotika is given as an intravenous (IV) injection, which is a method designed to achieve a rapid effect. The medication is used in acute situations where rapid circulatory support is required, such as treating low blood pressure during anesthesia.


Q: What kind of common over-the-counter medicines should be checked for interactions with Ephedrin Biotika?

A: Regulatory warnings highlight the need to avoid other medicines that have a similar stimulant effect. This includes sympathomimetic agents like pseudoephedrine, which are often found in over-the-counter cold and flu preparations. Official labeling also advises against the use of stimulant-containing dietary supplements.


Q: Is Ephedrin Biotika generally used for short-term or long-term conditions?

A: According to official product information, Ephedrin Biotika is indicated for the treatment of clinically important hypotension (low blood pressure) that occurs during anesthesia. The condition is acute, and administration is typically on an as-needed basis during a procedure, consistent with short-term treatment.


Q: How does Ephedrin Biotika work in the body, in simple terms?

A: Ephedrine is officially classified as an adrenergic agonist and a norepinephrine-releasing agent. In simple terms, its action is described as mimicking and amplifying the body's natural stress response, often called the 'fight or flight' response, to help raise blood pressure and heart rate.


Q: Why is Ephedrin Biotika sometimes confused with decongestants?

A: Ephedrine is a sympathomimetic drug that has multiple actions. While its primary role is to affect the circulatory system, official documents confirm it also causes bronchodilation (widening of the airways). This specific respiratory action is shared with many common decongestant medicines, which can lead to confusion about its primary intended use.


Q: What are the signs of taking too much Ephedrin Biotika?

A: Since this medication is administered in a controlled clinical setting, exposure to excessive amounts is closely monitored. Official safety documents indicate that severe reactions may include pronounced tachycardia (a very fast heart rate) and severe hypertension (dangerously high blood pressure).


Q: Are there any known interactions between Ephedrin Biotika and herbal supplements?

A: Official labeling includes advice to avoid dietary supplements that contain stimulant effects. Although specific herbal supplements are not listed by name, any supplement containing stimulants would fall under this category due to the potential for interactions.


Q: How does the action of Ephedrin Biotika differ from general decongestants?

A: General decongestants typically work by constricting blood vessels. Ephedrine has multiple systemic effects. Regulatory information describes its dual action, which includes affecting both blood vessels (vasoconstriction) and the heart (increasing heart rate and contractility).


Q: What is the function of the specific 'Biotika' formulation of ephedrine?

A: The 'Biotika' name is a brand-specific formulation. Its function is to provide the active substance, Ephedrine hydrochloride, as a sterile solution suitable for intravenous administration. This injectable format is necessary to achieve the rapid action required for its approved use.


Q: Does Ephedrin Biotika contain any common allergens or inactive ingredients I should know about?

A: Official documents list all inactive ingredients, or excipients, within the solution. For example, some formulations contain sodium (salt), which is listed in the excipient section for patients who may require a controlled sodium intake.


Q: How long after stopping other stimulant medicines is it safe to start Ephedrin Biotika?

A: For certain high-risk medications, such as Non-selective Monoamine Oxidase Inhibitors (MAOIs), regulatory documents specify a mandatory separation rule. Official prescribing information states there must be a mandatory separation period of 14 days after stopping the MAOI before Ephedrin Biotika can be administered.


Q: What should a patient do if they notice an unexpected reaction to Ephedrin Biotika?

A: Since the medicine is only administered by a healthcare professional, if a patient experiences severe or unexpected symptoms, official guidance suggests immediately notifying the healthcare provider for evaluation. Severe reactions are also formally reported to national health authorities for monitoring purposes.


Q: Can Ephedrin Biotika cause a dry mouth?

A: Yes, official safety documents and consumer information indicate that dry mouth or dryness of the nose and throat is a reported side effect of Ephedrine.


Q: Is Ephedrin Biotika banned in sports or competitive leagues?

A: Regulatory warnings inform athletes that this active substance might give a positive reaction in anti-doping tests because it belongs to the stimulant class.


Q: What should I be aware of regarding drug testing and Ephedrin Biotika?

A: This is noted in regulatory documents, advising that the active substance might give a positive reaction in anti-doping tests for athletes involved in competitive sports or leagues.

Advertisements

How should Ephedrin Biotika be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents strictly define how Ephedrin Biotika (Ephedrine hydrochloride solution for injection) must be stored to maintain its integrity and safety profile. The medicine must be kept out of the sight and reach of children.

Storage Requirement Official Condition
Temperature Store at or below 25 C to prevent degradation.
Light Protection Keep the ampoules in the original outer carton until use.
Stability Rule The solution is for single use only; any unused portion must be immediately discarded.

Disposal of Unused Product

Disposal must adhere to local pharmaceutical waste guidelines. Unused or expired Ephedrin Biotika must not be disposed of in household waste or poured down the drain, as official instructions require preventing the product from entering waterways or the environment. All medical waste should be discarded according to recognized waste disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ephedrin Biotika found in:

A-Z Index: